Organogenesis Holdings Inc (ORGO)

$2.41 -0.18 (-6.95%)
Market Cap 333.27M
Revenue (ttm) 564.17M
Net Income (ttm) 37.03M
EPS (ttm) N/A
PE Ratio 90.00
Forward PE N/A
Profit Margin 6.56%
Debt to Equity Ratio 0.00
Volume 1,948,400
Avg Vol 1,594,016
Day's Range N/A - N/A
Shares Out 128.68M
Stochastic %K 50%
Beta 1.31
Analysts Hold
Price Target $8.00

Company Profile

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatm...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 781 575 0775
Address:
85 Dan Road, Canton, United States
Mobagri
Mobagri May. 15 at 4:29 AM
$ORGO Mimidyx troll Monticello AKA sophisticated investor
0 · Reply
Monticello4
Monticello4 May. 14 at 8:59 PM
$ORGO Here is the real Mobagri, at his finest. Remember that he described himself as a sophisticated investor... sickening. These posts were sent to me and others...we agreed to delete the recipient's names
0 · Reply
Monticello4
Monticello4 May. 14 at 7:50 PM
$ORGO ...😁
0 · Reply
Monticello4
Monticello4 May. 14 at 6:49 PM
$ORGO ===
0 · Reply
Monticello4
Monticello4 May. 14 at 6:48 PM
$ORGO ..
0 · Reply
Monticello4
Monticello4 May. 14 at 6:47 PM
$ORGO ,
0 · Reply
Mobagri
Mobagri May. 13 at 9:15 PM
$ORGO the higher it goes the more Monticello appetite gets. Fuck Mimidyx
0 · Reply
justkeepgoing
justkeepgoing May. 13 at 8:45 PM
$ORGO what is up with $ORGO today? The uptick isn’t industry wide.
0 · Reply
Dukefurer
Dukefurer May. 13 at 7:57 PM
$ORGO Buy EZGO
0 · Reply
Raiderdave98
Raiderdave98 May. 13 at 7:16 PM
$ORGO how does the shake up of the FDA affect our approval chances?
0 · Reply
Latest News on ORGO
Organogenesis downgraded to Neutral from Buy at BTIG

2026-05-08T11:17:55.000Z - 7 days ago

Organogenesis downgraded to Neutral from Buy at BTIG

Organogenesis Holdings Earnings Call Transcript: Q1 2026

May 7, 2026, 5:00 PM EDT - 8 days ago

Organogenesis Holdings Earnings Call Transcript: Q1 2026

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

May 7, 2026, 4:05 PM EDT - 8 days ago

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

Organogenesis completes rolling submission of ReNu BLA

2026-04-28T22:00:57.000Z - 17 days ago

Organogenesis completes rolling submission of ReNu BLA

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

Apr 28, 2026, 4:30 PM EDT - 17 days ago

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

Why is Organogenesis Stock (ORGO) Up 20% Today?

2026-04-07T12:03:59.000Z - 5 weeks ago

Why is Organogenesis Stock (ORGO) Up 20% Today?

Organogenesis achieves primary endpoint in PuraPly study

2026-04-06T23:05:09.000Z - 5 weeks ago

Organogenesis achieves primary endpoint in PuraPly study

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

Apr 6, 2026, 7:02 PM EDT - 5 weeks ago

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

Organogenesis announces successful FDA meeting, plans to file BLA for ReNu

2026-04-06T21:35:17.000Z - 5 weeks ago

Organogenesis announces successful FDA meeting, plans to file BLA for ReNu

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

Apr 6, 2026, 5:30 PM EDT - 5 weeks ago

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

Apr 6, 2026, 7:30 AM EDT - 5 weeks ago

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

Organogenesis price target lowered to $8 from $9 at BTIG

2026-02-27T12:39:51.000Z - 2 months ago

Organogenesis price target lowered to $8 from $9 at BTIG

Organogenesis Holdings Earnings Call Transcript: Q4 2025

Feb 26, 2026, 5:00 PM EST - 2 months ago

Organogenesis Holdings Earnings Call Transcript: Q4 2025

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

Feb 26, 2026, 4:05 PM EST - 2 months ago

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

Feb 19, 2026, 4:05 PM EST - 3 months ago

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

Organogenesis initiates rolling submission of BLA to FDA for ReNu

2025-12-23T21:10:37.000Z - 5 months ago

Organogenesis initiates rolling submission of BLA to FDA for ReNu

Organogenesis Announces Initiation of Biologics License Application for ReNu®

Dec 23, 2025, 4:05 PM EST - 5 months ago

Organogenesis Announces Initiation of Biologics License Application for ReNu®

Organogenesis plans to file BLA for ReNu before end of December

2025-12-15T21:30:39.000Z - 5 months ago

Organogenesis plans to file BLA for ReNu before end of December

Organogenesis price target raised to $9 from $7 at BTIG

2025-11-20T12:16:47.000Z - 6 months ago

Organogenesis price target raised to $9 from $7 at BTIG

Organogenesis Holdings Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 6 months ago

Organogenesis Holdings Earnings Call Transcript: Q3 2025

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

Nov 6, 2025, 4:05 PM EST - 6 months ago

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

Organogenesis Applauds CMS's Significant Step In Payment Reform

Nov 3, 2025, 1:10 PM EST - 6 months ago

Organogenesis Applauds CMS's Significant Step In Payment Reform

Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 31, 2025, 4:05 PM EDT - 7 months ago

Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO

Oct 17, 2025, 2:20 PM EDT - 7 months ago

Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025

Oct 1, 2025, 4:05 PM EDT - 8 months ago

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025

Organogenesis provides update on second Phase 3 ReNu study

2025-09-25T20:55:11.000Z - 8 months ago

Organogenesis provides update on second Phase 3 ReNu study

Organogenesis Provides Update on Second Phase 3 ReNu® Study

Sep 25, 2025, 4:50 PM EDT - 8 months ago

Organogenesis Provides Update on Second Phase 3 ReNu® Study

Organogenesis Holdings Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 2:10 PM EDT - 9 months ago

Organogenesis Holdings Transcript: Cantor Global Healthcare Conference 2025

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

Aug 27, 2025, 4:05 PM EDT - 9 months ago

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

Organogenesis Holdings Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Organogenesis Holdings Earnings Call Transcript: Q2 2025

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 10 months ago

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

Jul 22, 2025, 4:05 PM EDT - 10 months ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation

Jul 15, 2025, 9:00 AM EDT - 10 months ago

Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation

Organogenesis Holdings Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

Organogenesis Holdings Earnings Call Transcript: Q1 2025

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 1 year ago

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness

Apr 11, 2025, 4:05 PM EDT - 1 year ago

Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

Apr 7, 2025, 4:05 PM EDT - 1 year ago

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

Organogenesis Holdings Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

Organogenesis Holdings Earnings Call Transcript: Q4 2024

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025

Jan 27, 2025, 7:30 AM EST - 1 year ago

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025

Organogenesis Expands Manufacturing Capacity to Support Future Growth

Nov 22, 2024, 4:05 PM EST - 1 year ago

Organogenesis Expands Manufacturing Capacity to Support Future Growth

Organogenesis Commends Final LCDs

Nov 15, 2024, 9:25 AM EST - 1 year ago

Organogenesis Commends Final LCDs

Organogenesis Holdings Earnings Call Transcript: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Organogenesis Holdings Earnings Call Transcript: Q3 2024

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

Nov 12, 2024, 4:01 PM EST - 1 year ago

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Nov 11, 2024, 5:05 PM EST - 1 year ago

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024

Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers

Oct 1, 2024, 4:05 PM EDT - 1 year ago

Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers

Organogenesis Holdings Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 18, 2024, 1:20 PM EDT - 1 year ago

Organogenesis Holdings Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Organogenesis Holdings Earnings Call Transcript: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 1 year ago

Organogenesis Holdings Earnings Call Transcript: Q2 2024

Organogenesis Shares ReNu® Program Update

Aug 8, 2024, 4:04 PM EDT - 1 year ago

Organogenesis Shares ReNu® Program Update

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

Jul 15, 2024, 4:05 PM EDT - 1 year ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference

Jun 6, 2024, 4:05 PM EDT - 2 years ago

Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference

Organogenesis Holdings Earnings Call Transcript: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Organogenesis Holdings Earnings Call Transcript: Q1 2024

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis

May 2, 2024, 7:00 AM EDT - 2 years ago

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

Apr 16, 2024, 7:30 AM EDT - 2 years ago

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

Organogenesis Holdings Earnings Call Transcript: Q4 2023

Feb 29, 2024, 5:00 PM EST - 2 years ago

Organogenesis Holdings Earnings Call Transcript: Q4 2023

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

Feb 29, 2024, 4:05 PM EST - 2 years ago

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Feb 12, 2024, 7:30 AM EST - 2 years ago

Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024

Feb 8, 2024, 4:05 PM EST - 2 years ago

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024

Organogenesis Holdings Earnings Call Transcript: Q3 2023

Nov 9, 2023, 5:00 PM EST - 2 years ago

Organogenesis Holdings Earnings Call Transcript: Q3 2023

Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:05 PM EST - 2 years ago

Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023

Oct 5, 2023, 7:30 AM EDT - 2 years ago

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023

Organogenesis Applauds Withdrawal of Local Coverage Determinations by Novitas, First Coast Service Options and CGS

Sep 28, 2023, 9:15 AM EDT - 2 years ago

Organogenesis Applauds Withdrawal of Local Coverage Determinations by Novitas, First Coast Service Options and CGS

Organogenesis Holdings Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Organogenesis Holdings Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 6, 2023, 4:05 PM EDT - 2 years ago

Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Organogenesis Holdings Earnings Call Transcript: Q2 2023

Aug 9, 2023, 5:00 PM EDT - 3 years ago

Organogenesis Holdings Earnings Call Transcript: Q2 2023

Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance

Aug 9, 2023, 4:05 PM EDT - 3 years ago

Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023

Jul 10, 2023, 7:30 AM EDT - 3 years ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023

TipRanks reveals the top 10 health care sector analysts of the past decade

May 21, 2023, 8:20 AM EDT - 3 years ago

TipRanks reveals the top 10 health care sector analysts of the past decade

CABA CYH EXAS MRNA NVAX PFE RARE

Organogenesis Holdings Earnings Call Transcript: Q1 2023

May 10, 2023, 5:00 PM EDT - 3 years ago

Organogenesis Holdings Earnings Call Transcript: Q1 2023

Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results

May 10, 2023, 4:05 PM EDT - 3 years ago

Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results

Organogenesis President and Chief Executive Officer Gary S. Gillheeney, Sr. Elected Chair of the Board of Directors

Apr 27, 2023, 7:30 AM EDT - 3 years ago

Organogenesis President and Chief Executive Officer Gary S. Gillheeney, Sr. Elected Chair of the Board of Directors

Mobagri
Mobagri May. 15 at 4:29 AM
$ORGO Mimidyx troll Monticello AKA sophisticated investor
0 · Reply
Monticello4
Monticello4 May. 14 at 8:59 PM
$ORGO Here is the real Mobagri, at his finest. Remember that he described himself as a sophisticated investor... sickening. These posts were sent to me and others...we agreed to delete the recipient's names
0 · Reply
Monticello4
Monticello4 May. 14 at 7:50 PM
$ORGO ...😁
0 · Reply
Monticello4
Monticello4 May. 14 at 6:49 PM
$ORGO ===
0 · Reply
Monticello4
Monticello4 May. 14 at 6:48 PM
$ORGO ..
0 · Reply
Monticello4
Monticello4 May. 14 at 6:47 PM
$ORGO ,
0 · Reply
Mobagri
Mobagri May. 13 at 9:15 PM
$ORGO the higher it goes the more Monticello appetite gets. Fuck Mimidyx
0 · Reply
justkeepgoing
justkeepgoing May. 13 at 8:45 PM
$ORGO what is up with $ORGO today? The uptick isn’t industry wide.
0 · Reply
Dukefurer
Dukefurer May. 13 at 7:57 PM
$ORGO Buy EZGO
0 · Reply
Raiderdave98
Raiderdave98 May. 13 at 7:16 PM
$ORGO how does the shake up of the FDA affect our approval chances?
0 · Reply
Monticello4
Monticello4 May. 13 at 7:03 PM
$ORGO =--=
0 · Reply
Monticello4
Monticello4 May. 13 at 7:02 PM
$ORGO ...
0 · Reply
Monticello4
Monticello4 May. 13 at 5:07 PM
$ORGO ha!
0 · Reply
Monticello4
Monticello4 May. 13 at 5:06 PM
$ORGO ===
0 · Reply
Monticello4
Monticello4 May. 13 at 5:06 PM
$ORGO --...
0 · Reply
Mobagri
Mobagri May. 13 at 4:33 PM
$ORGO dumbass the stock is moving up because there is positive news on Renu. You stupid cunt. You love to be degraded publicly
0 · Reply
Mobagri
Mobagri May. 13 at 4:15 PM
$ORGO latest news from our Mimidyx friend Monticello
0 · Reply
josegodoy
josegodoy May. 13 at 3:55 PM
$ORGO 🧐
0 · Reply
Monticello4
Monticello4 May. 13 at 3:25 PM
$ORGO ...
0 · Reply
Monticello4
Monticello4 May. 13 at 3:10 PM
$ORGO the Village Idiot strikes again 😁
0 · Reply
Monticello4
Monticello4 May. 13 at 3:07 PM
$ORGO ...
0 · Reply
Monticello4
Monticello4 May. 13 at 2:56 PM
$ORGO @Mofagri Hey Demi Douche - I see all your calls are just as you predicted...nice to see ORGO at $EXPECTED 8...MSFT at $500....AND DXCM at $90...I have lots of other great predictions of yours...want me to post them so people can see how smart you are?
0 · Reply